Related Experiment Video
Updated: Jun 5, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Pharmacotherapy in Parkinson's disease: case studies
Tiago Mestre1, Joaquim J Ferreira
1Neurological Clinic Research Unit, Institute of Molecular Medicine, Lisbon School of Medicine, Lisbon, Portugal.
Therapeutic Advances in Neurological Disorders
|December 24, 2010
Summary
Parkinson's disease management requires personalized strategies due to its progressive nature. This study explores effective treatment options for varying disease stages, emphasizing current evidence-based approaches.
Area of Science:
- Neurology
- Neurodegenerative Diseases
- Pharmacology
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder with effective, yet not curative, treatments.
- Disease progression alters clinical presentation, complicating treatment strategies and guideline adherence.
- Emerging research explores disease-modifying therapies and novel therapeutic avenues.
Purpose of the Study:
- To illustrate personalized treatment management for Parkinson's disease across different disease stages and phenotypes.
- To discuss therapeutic alternatives based on the latest clinical evidence and guidelines.
- To highlight the complexity of adapting treatment algorithms to individual patient needs.
Main Methods:
- Case study analysis of three patients with Parkinson's disease at distinct stages.
- Review of current treatment guidelines for Parkinson's disease.
- Evaluation of recent clinical trial data and observational studies on Parkinson's disease therapies.
Main Results:
- Demonstrated varied treatment responses and challenges in managing Parkinson's disease progression.
- Highlighted the importance of individualized therapeutic approaches over standardized algorithms.
- Showcased the potential of novel drugs and strategies in modifying disease course.
Conclusions:
- Effective Parkinson's disease management necessitates tailored treatment plans adapting to disease progression and individual patient characteristics.
- Current therapeutic strategies, while managing symptoms, offer limited disease modification, underscoring the need for ongoing research.
- Integrating clinical guidelines with patient-specific data is crucial for optimizing Parkinson's disease care.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...